In this time of incredible promise for genomic medicine, the Genomes2People (G2P) Research Program in Translational Genomics and Health Outcomes, directed by Robert C. Green, MD, MPH, is creating a deep body of knowledge on the medical, behavioral and economic implications of genomic analysis. Through its research, G2P is helping to set the stage for the use of genomic information in promoting health, preventing or mitigating disease, and reducing healthcare costs.

Dr. Green will summarize his research program that for 15 years has focused on the collection of clinical outcomes data using multiple modalities, including randomized controlled trials (RCT), surveys, demonstration projects and other methodologies. Dr. Green will summarize key research studies and results that comprise the G2P Research Program. He will discuss the history of returning predictive genetic risk information, beginning with the REVEAL Study of returning APOE-related risks, and will present an overview of the projects that have rigorously tracked medical, behavioral and economic outcomes associated with evolving applications of genetic and genomic testing. These include: the PGen Study of consumer genetic testing; the MedSeq Project, a RCT exploring the integration of genome sequencing (GS) into the clinical care of healthy adults and adults with cardiomyopathy; the BabySeq Project, a RCT investigating the use of GS in screening healthy and sick infants for childhood risks and newborn illness; and the PeopleSeq Consortium, a longitudinal survey of ostensibly healthy cohorts that have received GS results. He will end by previewing upcoming initiatives and collaborations that are poised to inform the future implementation of genomic medicine, particularly in understudied populations and contexts with unique ELSI challenges.